Fibrin-based matrices for angio genic stimulation  by Zisch, Andreas H et al.
JOURNAL OF VASCULAR SURGERY 
Volume 31, Number 6 Lifeline Research Meeting Abstracts 1303 
in thrombotic events with heparin-coated Palmaz-Schatz 
stents in normal porcine coronary arteries. Circulation 
1996;93:423-30. 
41. Burchenal JEB, Marks DS, Mann JT, Schweiger MJ, 
Rothman MT, Ganz P, et al. Effect of direct thrombin inhi- 
bition with Bivalirudin (Hirulog) on restenosis after coronary 
angioplasty. Am J Cardiol 1998;82:511-5. 
42. van de WerfF. More evidence for a beneficial effect ofplatelet 
glycoprotein IIb/IIIa-blockade during coronary interven- 
tions: latest results from the EPILOG and CAPTURE trials. 
Circulation 1996;93:637. 
43. Aggarwal RK, Ireland DC, Azrin MA, Ezekowitz MD, 
deBono DP, Gershlick Ah. Antithrombotic potential of poly- 
mer-coated stents eluting platelet glycoprotein I Ib/ I I Ia 
receptor antibody. Circulation 1996;94:3311-7. 
44. Sollott SJ, Cheng L, Pauly RR, Jenkins GM, Monticone RE, 
Kuzuya M, et aft. Taxol inhibits neointimal smooth muscle 
cell accumulation after angioplasty in the rat. J Clin Invest 
1995;95:1869-76. 
45. Axel DI, Kunert W, Goggelmann C, OberhoffM, Herdeg C, 
Kuttner A, et al. Paclitaxel inhibits arterial smooth muscle cell 
proliferation and migration in vitro and in vivo using local 
drug delivery. Circulation 1997;96:636-45. 
FIBRIN-BASED MATRICES FOR ANGIO- 
GENIC STIMULATION 




J. C. Schense 
jr. A. Hubbell 
Inst#ute for Biomedical Engineering 
Zurich, Switzerland 
Our laboratory's research in vascular tissue engi- 
neering focuses on two distinct goals: first, in the 
context of building blood vessels dc novo, we aim to 
engineer biomaterial surfaces that are able to attract 
and retain endothelial cells organized as two-dimen- 
sional endothelial cell sheet under flow conditions, 
similar to the the native luminal vessel wall. Second, 
featuring the three-dimensional organization of 
endothelial cells, the generation of biomaterial 
matrices, which when grafted to the wounded or 
ischemic tissue, locally stimulate neovessel formation 
in the surrounding of the graft and also in the graft 
itself. In both cases, the material designs aim the vas- 
cular grafts to become populated in situ with 
endothelial cells derived from the body's endoge- 
nous sources (ie, from the artery adjacent to the 
graft, from existing blood vessels, or from circulat- 
ing endothelial progenitor cells). For that reason, 
these grafts must have properties pecifically attrac- 
tive for endothelial cells. Through basic research, a
better knowledge has been developed about the 
molecular aspects and requirements for reendothe- 
lialization and blood vessel formation. This biologi- 
cal information can be inferred on a biomaterial by 
incorporating peptide or protein motifs that are nec- 
essary for the recruitment and the binding of 
endothelial cell binding. Polypeptide growth factors, 
in particular vascular endothelial growth factor 
(VEGF), have evolved as critical for many aspects of 
endothelial cell biology, such as the maturation, the 
proliferation, the assembly, and the survival of 
endothelial cells. The Hubbell aboratory has recent- 
ly developed methodology that allows fibrin to be 
modified by covalent incorporation ofbioactive pep- 
tides or proteins during the coagulation process. 
The base matrix fibrin is a natural ingrowth matrix 
for endothelial cells. To confer the angiogenic fea- 
tures of VEGF upon fibrin, we used this methodol- 
ogy to covalently incorporate VEGF121, an other- 
wise diffusible VEGF isoform into the fibrin matrix. 
This VEGF121/fibrin matrix exhibits trong angio- 
genie responses both in vitro and in vivo as described 
below. Further, we will discuss a sophisticated and 
elegant fibrin modification scheme in which growth 
factors, such as the VEGF165 isoform, can be 
entrapped and retained within the matrix through 
their heparin-binding abilities. From these depots, 
growth factors can be released by controllable diffu- 
sion as well as the activity of matrix-degrading 
enzymes ecreted by cells invading the matrix. 
The clinical demand for angiogenic materials-- 
modified fibrin as material for clinics 
Design of materials that induce angiogenesis in
vivo is important for many areas of tissue regeneration 
and wound healing. One of the more relevant and 
therefore well studied needs is in treatment ofchronic 
wounds, such as diabetic ulcers, pressure ulcers, or 
venous tatic ulcers that are caused by deficient vascu- 
lar supply. Scores of trials with ulcer patients have been 
conducted over the past years using growth factor pro- 
reins or cytokines as therapeutics, with many discour- 
aging results. One likely explanation for the failure of 
many therapies i the current modes of growth factor 
delivery in the context of creams and sprays, which are 
often inappropriate for providing sustained delivery of 
active factors. Without enbedment, however, the solu- 
ble protein factors are cleared v ry rapidly from the 
target site, or never each the target in sufficient quan- 
rifles, or reach it only at extreme dose. For angiogenic 
stimulation with VEGF, this dilemma of delivering 
VEGF protein active is now attacked in parallel by tis- 
sue engineering and somatic gene therapy approaches. 
These include first, novel, "smarter" biomaterials that 
present the polypeptide growth factors properly and 
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therefore work with much smaller doses ofactive fac- 
tors; second, the in situ expression f the gene after 
intramuscular injection or adenovirus mediated eliv- 
ery of the DNA; and third, representing a combina- 
tion of point one and two, the use of so called gene 
activated matrices where the gene is added as plasmid 
into a biomatrbc that can be invaded by cells that pick 
up the DNA and subsequently express the gene prod- 
uct. Indeed, the results with VEGF gene therapy are 
encouraging for the treatment of myocardial and 
peripheral ischemia. 14 As vehicle for the delivery of 
the protein tself, modified fibrin represents anexcel- 
lent candidate material. Fibrin is nontoxic and as "fib- 
fin glue," accepted for clinical application. It can be 
readily formed irectly at the site of therapeutical need 
from a mix of the precursor solutions containing fib- 
rinogen, thrombin and factor XIIIa. Through novel 
methodology developed in the Hubbell laboratory, 
exogenously added peptides or proteins, modified by 
the N-terminal addition of the transglutamination 
substrate sequence NQEQVSPL, can be covalently 
attached to the fibrin network through the action of 
factor XIIIa during the coagulation process. 6 We have 
used this scheme toincorporate growth factor into the 
fibrin gel or to confer growth factor elease character- 
istics onto fibrin. Polypeptide growth factors are not 
freely diffusible when present ha tissues but associated 
with extracellular matrix components, such as heparan 
sulfate proteoglycans. The interaction with matrix 
components i  critical to stabilize the factors' active 
conformation. Degradation ofthe matrix components 
by cellular enzymes uch as heparinases or proteases 
then leads to the release of the growth factors in solu- 
ble form. We exploit he heparin-binding activity of 
many polypeptide growth factors to add a heparin- 
based release system to fibrin to mimic the growth fac- 
tors' natural presentation through eparan sulfate pro- 
teoglycans in the extracellular matrix. A synthetic 
heparin-binding peptide derived from antithrombin 
III is covalently incorporated into fibrin during the 
coagulation process to accomplish this. When heparin 
is added simultaneously into the mixture before coag- 
ulation, amatrix rich in heparin, in character similar to 
extracellular matrix, is created. Any growth factor 
entrapped within this matrix would then interact with 
the incorporated heparin molecules and be retained 
within the matrix.7, 8 The rate of diffusion of the 
growth factor out of the gel can be readily controlled 
by the chosen concentrations of hepann-binding pep- 
tide, hepafin, and growth factor in the fibrin gel. The 
heparin-binding VEGF165 isoform, which now 
became available in our laboratory, will be tested in 
this scheme. 
Fibrin loaded with VEGF121 promotes angio- 
genesis 
VEGF is present endogenously in several iso- 
forms, differing in molecular weight and their ability 
to bind heparin. 9 The isoform VEGF121 is a non- 
heparin-binding VEGF variant. Its mitogenic activity 
for endothelial ceils appears to be somewhat 
weaker compared with the heparin-binding variant 
VEGF165, and therefore the VEGF165 isoform has 
been favored for use in previous therapeutic studies. 
However, the different activities of VEGF variants 
might also reflect their differing abilities to bind to 
matrix components hat stabilize their active confor- 
mation. VEGF121 has been succesfully used in aden- 
oviral gene therapy for treatment of coronary artery 
disease. 4 In our studies, VEGF121 was covalently 
incorporated into fibrin. By that, its release was 
dependent on the stability of fibrin itself, as only 
degradation of fibrin should result in VEGF release. 
Incorporation was accomplished by generating 
through recombinant DNA methodology a novel 
molecule TG/VEGFI21, containing the factor XIIIa 
substrate sequence NQEQVSPL from ~2 plasmin 
inhibitor added to the aminoterminus. The protein 
was expressed and purified in E coli. In soluble form, 
this modified TG/VEGF retained its mitogenic activ- 
ity for endothelial cells that compared the published 
activity of unmodified VEGF121. The covalent incor- 
poration of TG/VEGF into fibrin was analyzed using 
radiolabeled TG/VEGF. One to 120 btg/mL gel was 
added to the precursor solutions, and over this range 
the amount of incorporated VEGF was linearly 
dependent on the amount of added growth factor, 
with a degree of incorporation ofapproximately 50%. 
Hence, because of the incomplete incorporation, the 
resulting matrix contained a combination ofboth free 
and matrix-bound VEGF and thus represented a 
matrix that combined both chemotactic and hapto- 
tactic features for endothelial cells. Angiogenic stimu- 
lation by the VEGF121/fibrin matrices was assayed in 
both three-dimensional endothelial cell cultures and 
the chick chorioallantoic assay. Human umbilical vein 
endothelial ceils or pulmonary aortic endothelial cells 
were cultured either directly in TG/VEGF fibrin gels 
that were formed by the addition of 1 btg of 
TG/VEGF per milliliter gel, or in plain fibrin gels that 
were formed adjacent to TG/VEGF loaded fibrin 
gels. Control cultures were seeded in fibrin only. 
Endothelial cells grown directly in TG/VEGF loaded 
fibrin or in unmodified fibrin in proximity to 
TG/VEGF loaded fibrin were viable over 2 weeks 
and very prominently exhibited all classical hallmarks 
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of angiogenesis, uch as capillary networks and cord 
formation. Notably, these characteristics were absent 
in cells cultured in isolated, unmodified fibrin. Using 
the chick chorioallantoic membrane (CAM) assay, we 
confirmed the strong angiogenic stimulation mediat- 
ed by TG/VEGF loaded fibrin in vivo. Fibrin gels of 
100 ~tL, loaded with 1 to 10 ~tg of TG/VEGF, were 
directly formed on the chorioallantoic membrane and 
microscopically analyzed after 3 days in culture. 
VEGF-loaded fibrin gels were strongly vascularized, 
whereas control gels made of fibrin only remained 
basically vessel free. 
Prospects for angiogenic therapy 
It is likely, that somatic gene therapy and engi- 
neered biomaterials will compete friendly for better 
angiogenic performance, which is good news for hun- 
dreds, thousands, or millions of patients uffering 
from tissue ischemia or impaired wound healing 
worldwide. A certain beauty shared by both 
approaches, intramuscular gene delivery with "naked" 
eDNA, as well as protein delivery through modified 
fibrin, is the fact that formulation respective material 
generation is relatively simple, which may facilitate 
their approval as clinical tools. Yet a big demand 
remains for technical solutions that allow the admin- 
istration of these therapeutics inside the body with 
minimal invasion. But fibrin gels can be readily 
formed in the wound bed of chronic skin ulcers. One 
of our laboratory's immediate goals is to test if fibrin- 
based delivery systems with various growth factors, 
including VEGF, improve wound healing in skin. We 
hope that one of these growth factors will ride the 
fibrin horse for therapy in man. 
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